Data in this annual Report, published in June 2024, cover the period between January 1, 2023, and December 31, 2023, unless otherwise indicated. Disclosures in this Report should be reviewed in conjunction with our ESG Policies & Positions. Reporting on other matters specific to the financial performance of the Company and its subsidiaries can be found in our 2023 Annual Report. This Report covers Johnson & Johnson’s worldwide operations across our two business segments, Innovative Medicine and MedTech. Contract manufacturers are excluded from the scope of this Report, unless otherwise noted. References in this Report to “Johnson & Johnson,” “J&J,” “the Company,” “we,” “us” and “our” all refer to Johnson & Johnson and its consolidated subsidiaries, unless otherwise stated or indicated by context. All monetary references to dollars ($) refer to U.S. Dollars (USD).
This Report also covers some activities of the Johnson & Johnson Foundation, a registered charity and a company limited by guarantee. The Foundation is a separate legal entity from Johnson & Johnson and is funded solely by Johnson & Johnson. The Foundation operates worldwide as Johnson & Johnson Foundation United States (founded 1953) and Johnson & Johnson Foundation Scotland (founded 2007). More details on Foundation activities can be found in the Johnson & Johnson Foundation United States 2023 Annual Report and the Johnson & Johnson Foundation Scotland 2023 Directors’ Report.
The Report has been prepared to align with leading ESG standards and frameworks, including:
- Global Reporting Initiative (GRI) Standards (In Accordance);
- Sustainability Accounting Standards Board (SASB) Standards: HC-BP, HC-MS;
- Norges Bank Investment Management and Basel Institute on Governance’s “Measuring effectiveness of anti-corruption programmes” reporting framework.
See our ESG Performance Data and Indices for disclosures against these standards and frameworks. We also disclose to the UN Global Compact (UNGC); see our annual Communication on Progress.
Materiality approach2
The content in this Report is aligned with our Priority Topics Assessment, which helps us identify and prioritize the ESG topics that are most relevant to our business. See ESG governance and strategy.
Independent review and assurance
ERM Certification and Verification Services (ERM CVS) conducted an independent review and assurance of progress against our Health for Humanity Goals and associated data, and selected information and data in this Report: See ERM’s Assurance Statements. PricewaterhouseCoopers LLP (PwC) performed limited assurance on certain data as listed in the Report of Independent Accountants and Management’s Assertion. (See PwC’s Report of Independent Accountants and Management’s Assertion): Our internal Global Audit & Assurance organization reviewed select data for accuracy, completeness and validity. The financial data and general information about the business in this Report were previously audited for disclosure in our 2023 Annual Report.
Acquisitions
EH&S data of recently acquired companies, except for employee road safety data and site ISO and OHSAS certification data, are included in the Report 2 years after acquisition, unless otherwise noted. This approach allows the new acquisitions to adjust their EH&S management and reporting systems to J&J standards. ISO and OHSAS certification data are integrated 3 years after acquisition. All data from Abiomed, which was acquired in late December 2022, are included in this Report, with the following exceptions: CO2 Capital Relief Fund; EH&S Compliance and Certifications; Energy Use; Greenhouse Gas (GHG) emissions; Operational Waste; Supply Base Overview; Diverse Supplier Spend in the U.S. and globally; Supplier Engagement; Supplier Audits; and Water Use. The dates and details of recent acquisitions can be found in Note 18 (Acquisitions and Divestitures) in our 2023 Annual Report.
Divestitures and Consumer Health separation
Except for injury statistics and violations or fines, EH&S data of divested companies are excluded in the reporting year. In November 2021, the Company announced its intention to separate the Company’s Consumer Health business into a new, publicly traded company, now Kenvue. Kenvue data are not included in this Report and are omitted from the 2023 data in the ESG Performance Data and Indices section of this Report. No prior-year data from 2022 and 2021 have been restated following the Kenvue separation, unless specifically noted.
Restatements
We use a 5% change threshold to apply to significant changes in data or information that is restated, unless otherwise noted. There are several potential reasons that may lead to a restatement of either prior periods or baseline data (e.g., a significant change in newly published measures, new acquisitions or divestitures, data errors or improvements in data collection methodology over time). ESG performance data from 2022 and 2021 have not been restated to omit Kenvue data unless specifically noted. Depending on circumstances, each is evaluated using this threshold, and appropriate disclosures are included in the Report. Data that were not disclosed in prior years are noted as “not reported” in relevant tables throughout the Report.
Contact us: We welcome your queries and feedback on this Report. Please contact the Johnson & Johnson Office of the Corporate Secretary at: WW-Corporate-Governance@its.jnj.com.
Please visit the Reporting hub for our archive of annual Health for Humanity Reports.
2 Materiality as used in this Report and our PTA process are different than the definitions used in the context of filings with the U.S. Securities and Exchange Commission and other global reporting frameworks.
